You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Avacta doses first patient in pivotal phase 1a trial

Avacta – a company developing targeted oncology drugs and diagnostics – has announced that the first individual has been dosed with its AVA6000 candidate.